Abstract: The present invention discloses a method for treating heart rhythm disturbances in a mammal in need thereof by the administration of N6-substituted-5′-(N-substituted)carboxamidoadenosines.

Abstract: The present invention discloses a method for treating heart rhythm disturbances in a mammal in need thereof by the administration of N6-substituted-5′-(N-substituted)carboxamidoadenosines.

Abstract: The present invention discloses a method for treating heart rhythm disturbances in a mammal in need thereof by the administration of N6-substituted-5′(N-substituted)carboxamidoadenosines. More particularly, the invention is directed to a method for treatment of heart rhythm disturbances in a mammal that would benefit from the induction of negative dromotropic and/or negative chronotropic actions, comprising the administration to said mammal an effective amount of a compound of the Formula: or a pharmaceutically acceptable salt or ester thereof; wherein R1 is C3-7 secondary alkyl, or C3-8 cycloalkyl; and R2 is C1-4 alkyl or C3-5 cycloalkyl The invention is also directed to novel dosage forms comprising said compounds.

Abstract: In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A2A receptors can reduce or prevent such restenosis. This method may be achieved either by: (a) the administration of selective adenosine A2A receptor agonists, (b) the administration of a selective adenosine A1 antagonist in combination with either a selective adenosine A2A receptor agonist or a non-selective adenosine agonist, or (c) the administration of a selective adenosine A1 antagonist in order to block adenosine A1 receptor activation by endogenously-released adenosine. The present invention is also directed to an improved surgical procedure that relies upon selective stimulation of adenosine A2A receptors.

Abstract: In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A2A receptors can reduce or prevent such restenosis. This method may be achieved either by: (a) the administration of selective adenosine A2A receptor agonists, (b) the administration of a selective adenosine A1 antagonist in combination with either a selective adenosine A2A receptor agonist or a non-selective adenosine agonist, or (c) the administration of a selective adenosine A1 antagonist in order to block adenosine A1 receptor activation by endogenously-released adenosine. The present invention is also directed to an improved surgical procedure that relies upon selective stimulation of adenosine A2A receptors.

Abstract: In the present invention, a method is provided which reduces or prevents restenosis following revascularization procedures. It has now been found that selective stimulation of adenosine A2A receptors can reduce or prevent such restenosis. This method may be achieved either by: (a) the administration of selective adenosine A2A receptor agonists, (b) the administration of a selective adenosine A1 antagonist in combination with either a selective adenosine A2A receptor agonist or a non-selective adenosine agonist, or (c) the administration of a selective adenosine A1 antagonist in order to block adenosine A1 receptor activation by endogenously-released adenosine. The present invention is also directed to an improved surgical procedure that relies upon selective stimulation of adenosine A2A receptors.